VCP Scanner
Stock Screener
Filter stocks with fundamental & technical criteria
Market Themes
Curated industry baskets & thematic leaders
Earnings Hub
Calendar, EPS surprise stats & earnings transcripts
Market News
Real-time market intelligence & AI overviews
Insider Buying
SEC Form 4 corporate insider purchases
LearnAll lessons
Candlestick Patterns44 candles, each on two real charts
Pattern GuidesThe playbooks' setups on real breakouts
GlossaryInvesting terms in plain English
MinerviniVCP SetupsTrend Template
O'NeilCup with HandleFlat BaseDouble BottomCANSLIM Leaders
QullamaggieHigh Tight FlagsFlag BreakoutsEpisodic PivotsMomentum Leaders
KellWedge PopEMA Crossback
LivermorePivotal Points
PatternsFalling Wedge & ChannelBase Breakouts
View All Playbooks...
BreakoutsScanner
FAANG & Tech
AAPL vs MSFTNVDA vs AMDGOOGL vs META
Cloud & Cyber
CRM vs NOWCRWD vs PANWSNOW vs DDOG
Consumer & Auto
TSLA vs FAMZN vs WMTNFLX vs DIS
Finance & Crypto
JPM vs BACV vs MACOIN vs MSTR
Index & ETFs
SPY vs QQQVTI vs VOOSPY vs IWM
Compare Any Stocks...
DCF ValuationCalculate intrinsic value of US stocks
Market ValuationBuffett indicator, CAPE & macro gauges
Total ReturnSee dividends + price return history
DCA CalculatorSimulate recurring buys & compounding
VisualizeInteractive multi-year financial charts
Watchlist
BreakoutsScanner
WatchlistPricing
Ctrl K
Pricing
IEX
← Back to Screener
VCP ScannerFree US Stock Screener & Financial Analysis

Find stocks. Analyze deeply. Research with clarity.

Data updated daily

Product

  • Screener
  • Scanner
  • Themes
  • Valuation
  • Total Return
  • DCA Calculator
  • Pricing
  • News
  • Earnings

Resources

  • Market Valuation
  • Compare
  • Insider Activity
  • Methodology
  • How It Works
  • Glossary
  • Learn

Get Ideas

Get weekly market insights — free

© 2026 VCP Scanner
AboutPrivacyTermsRefund Policy
Not financial advice. Do your own research.
ScreenerBreakoutsScannerWatchlist
IEXIDEX Corporation
$233.14$17.2B
Overview & Tools
OverviewChart Terminal ↗Visualize
Valuation & Forecasts
Valuation ModelsEstimatesDCF Model
Price & Analyst Data
Analyst TargetsPrice History
Financial Statements
Income StatementBalance SheetCash FlowRatios & Margins
Performance
P/E HistoryRevenue HistoryEarnings HistoryDividend HistoryTotal Return
Discovery & Screens
Live BreakoutsStock ScreenerOwnership
HomeStocksIEXFinancials

IDEX Corporation (IEX) Income Statement

30Y historyFree accessUpdated daily

Revenue rose 8.3% year over year to $951.7M in 2026Q3 while operating margin reached 21.9% and gross margin recovered to 45.1%, though gains may partly reflect favorable timing.

Income StatementBalance SheetCash FlowRatios

IEX Income Statement

Annual statement

IEX Income Statement

IDEX Corporation (IEX) annual income statement — 30-year revenue, gross profit & net income history

AnnualQuarterly
MetricTTMDec'25Dec'24Dec'23Dec'22Dec'21Dec'20Dec'19Dec'18Dec'17Dec'16Dec'15Dec'14Dec'13Dec'12Dec'11Dec'10Dec'09Dec'08Dec'07Dec'06Dec'05Dec'04Dec'03Dec'02Dec'01Dec'00Dec'99Dec'98Dec'97Dec'96
Sales/Revenue3.66B3.46B3.27B3.27B3.18B2.76B2.35B2.49B2.48B2.29B2.11B2.02B2.15B2.02B1.95B1.84B1.51B1.33B1.49B1.36B1.15B1.04B928.3M797.92M742.01M726.95M704.28M655M640.1M552.2M562.6M
Revenue Growth %6.93%5.77%-0.16%2.89%15.09%17.57%-5.73%0.44%8.58%8.25%4.57%-5.92%6.11%3.58%6.3%21.5%13.79%-10.73%9.63%17.64%10.7%12.39%16.34%7.53%2.07%3.22%7.52%2.33%15.92%-1.85%15.45%
Cost of Goods Sold2.02B1.92B1.75B1.65B1.59B1.4B1.19B1.22B1.32B1.22B1.13B1.08B1.16B1.12B1.11B1.05B862.79M777.67M862.54M762.08M652.73M573.49M536.26M488.6M460.58M463.23M401.42M375.1M364.5M313.1M329.5M
COGS % of Revenue-55.49%53.6%50.43%49.89%50.76%50.76%48.94%53.06%53.26%53.39%53.42%54.03%55.13%57.01%56.95%57.02%58.49%57.91%56.09%56.52%54.97%57.77%61.23%62.07%63.72%57%57.27%56.94%56.7%58.57%
Gross Profit1.64B1.54B1.52B1.62B1.59B1.36B1.16B1.27B1.17B1.07B984.87M941.32M987.41M908.16M840.1M791.35M650.16M551.09M626.95M596.55M502.21M437.77M392.04M309.32M281.44M263.72M302.86M279.9M275.6M239.1M233.1M
Gross Margin %44.87%44.51%46.4%49.57%50.11%49.24%49.24%51.06%46.94%46.74%46.61%46.58%45.97%44.87%42.99%43.04%42.97%41.45%42.09%43.91%43.48%41.96%42.23%38.77%37.93%36.28%43%42.73%43.06%43.3%41.43%
Gross Profit Growth %-1.46%-6.54%1.78%17.11%17.58%-9.1%9.26%9.06%8.55%4.63%-4.67%8.73%8.1%6.16%21.72%17.98%-12.1%5.1%18.79%14.72%11.66%26.74%9.91%6.72%-12.92%8.2%1.56%15.27%2.57%16.09%
Operating Expenses875.2M818.8M819.8M872.1M804.9M707.5M621.13M672.09M581.72M566.04M533.69M510.41M539.52M509.45M480.89M451.9M390.07M355.05M372.89M341.47M285M256.74M242.65M199.46M181.27M179.06M186.34M175.3M166.1M135.5M134.7M
OpEx % of Revenue-23.68%25.08%26.64%25.3%25.59%26.41%26.94%23.42%24.75%25.26%25.26%25.12%25.17%24.61%24.58%25.78%26.7%25.04%25.13%24.68%24.61%26.14%25%24.43%24.63%26.46%26.76%25.95%24.54%23.94%
Selling, General & Admin861.6M818.8M749M696.2M648.1M573.2M490.63M523.29M533.72M523.64M494.29M476.81M502.72M476.45M444.49M415.9M358.27M325.45M343.39M313.37M260.2M232.94M221.41M199.46M181.27M164.89M149.64M140.5M132.6M110.6M111.5M
SG&A % of Revenue-23.68%22.91%21.27%20.37%20.73%20.86%20.98%21.49%22.89%23.39%23.6%23.41%23.54%22.74%22.62%23.68%24.48%23.05%23.06%22.53%22.33%23.85%25%24.43%22.68%21.25%21.45%20.72%20.03%19.82%
Research & Development00178.6M175.9M156.8M133M130.5M148.8M48M42.4M39.4M33.6M36.8M33M36.4M36M31.8M29.6M29.5M28.1M24.8M23.8M21.24M00000000
R&D % of Revenue--5.46%5.37%4.93%4.81%5.55%5.96%1.93%1.85%1.86%1.66%1.71%1.63%1.86%1.96%2.1%2.23%1.98%2.07%2.15%2.28%2.29%--------
Other Operating Expenses3M0-107.8M001.3M000000000000000000014.16M36.7M34.8M33.5M24.9M23.2M
Operating Income766.3M720M696.9M750.7M789.5M654M536.79M601.75M584.17M503.04M451.17M430.91M447.9M398.71M359.21M339.44M260.08M196.03M254.06M255.08M217.21M181.03M149.38M109.86M100.37M73.44M116.52M104.6M109.5M103.6M98.4M
Operating Margin %20.95%20.82%21.32%22.93%24.81%23.65%22.83%24.12%23.52%21.99%21.35%21.32%20.85%19.7%18.38%18.46%17.19%14.74%17.06%18.77%18.81%17.35%16.09%13.77%13.53%10.1%16.54%15.97%17.11%18.76%17.49%
Operating Income Growth %-3.31%-7.17%-4.91%20.72%21.84%-10.79%3.01%16.13%11.5%4.7%-3.79%12.34%11%5.82%30.51%32.67%-22.84%-0.4%17.44%19.98%21.19%35.97%9.45%36.68%-36.97%11.39%-4.47%5.7%5.28%14.15%
EBITDA980.3M926.5M872.5M902.8M909.2M757M620.29M678.65M661.72M587.25M538.07M509.03M524.8M478.05M437.52M411.83M318.19M252.38M302.66M293.58M247.62M211.68M180.91M139.92M130.48M117.73M153.22M139.4M143M128.5M121.6M
EBITDA Margin %26.8%26.8%26.69%27.58%28.57%27.38%26.38%27.2%26.64%25.67%25.46%25.19%24.43%23.62%22.39%22.4%21.03%18.98%20.32%21.61%21.44%20.29%19.49%17.54%17.58%16.2%21.76%21.28%22.34%23.27%21.61%
EBITDA Growth %7.7%6.19%-3.36%-0.7%20.11%22.04%-8.6%2.56%12.68%9.14%5.7%-3.01%9.78%9.26%6.24%29.43%26.08%-16.61%3.09%18.56%16.98%17.01%29.3%7.23%10.82%-23.16%9.91%-2.52%11.28%5.67%17.72%
D&A (Non-Cash Add-back)214M206.5M175.6M152.1M119.7M103M83.5M76.9M77.54M84.22M86.89M78.12M76.91M79.33M78.31M72.39M58.11M56.35M48.6M38.5M30.41M30.65M31.53M30.05M30.11M44.3M36.7M34.8M33.5M24.9M23.2M
EBIT766.2M697M683.8M812M790.1M617.5M521.11M570.92M579.55M506.82M420.98M426.95M427.11M387.9M120.82M297.02M239.22M177.89M211.43M258.52M218.25M181.59M148.64M109.86M100.17M84.66M116.52M104.6M109.5M103.6M87.7M
Net Interest Income-62.7M-64.4M-44.5M-51.7M-40.7M-37.7M-50.77M-38.01M-50.61M-51.54M-52.47M-34.61M-34.67M-34.78M-34.61M-23.14M-7.34M-9.07M-19.2M-23.35M-16.35M-14.37M-14.76M00000000
Interest Income0000000000000000000000000000000
Interest Expense62.7M64.4M44.5M51.7M40.7M37.7M50.77M38.01M50.61M51.54M52.47M34.61M34.67M34.78M34.61M23.14M7.34M9.07M19.2M23.35M16.35M14.37M14.76M00000000
Other Income/Expense-62.8M-87.4M-57.6M9.6M-40.1M-74.2M-66.45M-68.84M-55.23M-47.77M-82.66M-38.56M-55.46M-45.58M-273.01M-65.56M-28.21M-27.21M-61.83M-19.92M-15.31M-13.81M-15.51M-13.19M-16.48M-20.01M-15.49M-17.4M-21.8M-19.1M-8.8M
Pretax Income703.5M632.6M639.3M760.3M749.4M579.8M470.34M532.9M528.94M455.27M368.51M392.35M392.44M353.13M86.2M273.88M231.87M168.83M198.7M235.16M201.89M168.93M133.88M96.67M83.89M53.43M101.03M87.2M87.7M84.5M78.9M
Pretax Margin %19.23%18.3%19.56%23.22%23.55%20.97%20%21.36%21.3%19.9%17.44%19.42%18.27%17.45%4.41%14.9%15.32%12.7%13.34%17.31%17.48%16.19%14.42%12.12%11.31%7.35%14.34%13.31%13.7%15.3%14.02%
Income Tax167.9M150.1M134.7M164.7M162.7M130.5M92.56M107.38M118.37M118.02M97.4M109.54M113.05M97.91M48.57M80.02M74.77M55.44M67.34M79.3M68.17M59.13M47.47M34.32M29.78M20.72M37.58M32.8M33.3M31M28.7M
Effective Tax Rate %23.87%23.73%21.07%21.66%21.71%22.51%19.68%20.15%22.38%25.92%26.43%27.92%28.81%27.73%56.35%29.22%32.25%32.84%33.89%33.72%33.77%35%35.46%35.5%35.5%38.78%37.2%37.61%37.97%36.69%36.38%
Net Income535.8M483.2M505M596.1M586.9M449.4M377.8M425.52M410.57M337.26M271.11M282.81M279.39M255.22M37.63M193.86M157.1M113.39M131.36M155.15M146.67M109.8M86.41M62.35M54.11M32.71M63.45M54.4M64.6M58.7M50.2M
Net Margin %14.65%13.98%15.45%18.21%18.45%16.25%16.07%17.06%16.53%14.74%12.83%14%13.01%12.61%1.93%10.54%10.38%8.53%8.82%11.42%12.7%10.52%9.31%7.81%7.29%4.5%9.01%8.31%10.09%10.63%8.92%
Net Income Growth %12.07%-4.32%-15.28%1.57%30.6%18.95%-11.21%3.64%21.74%24.4%-4.14%1.22%9.47%578.22%-80.59%23.4%38.55%-13.68%-15.33%5.78%33.58%27.08%38.58%15.23%65.43%-48.44%16.63%-15.79%10.05%16.93%10.82%
Net Income (Continuing)535.6M482.5M504.6M595.6M586.7M449.3M377.78M425.52M410.57M337.26M271.11M282.81M279.39M255.22M37.63M193.86M157.1M113.39M127.03M155.86M133.72M108.58M86.41M62.35M54.11M32.71M63.45M54.4M54.4M53.5M44.4M
Discontinued Operations0000000000000000000001.23M000000000
Minority Interest-1.5M-1.3M-600K-200K300K0123K000000000000000000000000
EPS (Diluted)7.246.416.647.857.725.884.945.575.294.363.533.623.453.090.452.321.901.401.531.891.811.391.120.830.740.470.920.800.920.870.75
EPS Growth %13.92%-3.46%-15.41%1.68%31.29%19.03%-11.31%5.29%21.33%23.51%-2.49%4.93%11.65%586.67%-80.6%22.11%35.71%-8.5%-19.05%4.42%30.22%24.11%34.94%12.16%57.45%-48.91%15%-13.04%5.75%16%10.29%
EPS (Basic)-6.416.677.887.755.914.995.635.374.413.573.653.483.110.452.341.931.411.551.921.841.431.150.850.760.480.950.820.940.890.77
Diluted Shares Outstanding74M75.3M75.9M75.9M76M76.4M76.4M76.45M77.56M77.33M76.76M77.97M80.73M82.49M83.64M83.54M81.98M80.73M82.32M82.09M80.98M79.08M77.02M74.96M73.09M69.86M68.92M67.69M67.62M67.66M66.77M
Basic Shares Outstanding73.7M75.3M75.7M75.6M75.7M76M75.74M75.59M76.41M76.23M75.8M77.13M79.72M81.52M82.69M82.14M80.47M79.72M81.12M80.67M79.53M77.09M75.11M73.19M71.26M68M66.88M66.47M66M65.64M64.85M
Dividend Payout Ratio-44%40.65%31.99%30.23%35.85%40.18%34.59%31.05%32.96%37.86%34.01%30.68%28.57%170.31%28.17%29.49%34.07%29.99%24.02%20.72%22.48%24.78%29.32%32.75%52.16%26.45%30.33%24.46%23.85%24.5%

Key Metrics

Growth RegimeExpanding
ProfitabilityStrong
Balance SheetHealthy
Cash FlowStable
Top Statement Risk

Biopharma demand volatility in HST

Verified Source

Metrics are mathematically derived from official filings.

SEC 10-K (2026Q3)

Revenue Reaccelerating Toward Mid-Single-Digit Growth

Based on reported quarterly figures, IEX's revenue rose 8.3% year over year to $951.7M in 2026Q3, up from a 1.7% gain in 2025Q1, suggesting a meaningful reacceleration in top-line momentum over the past six quarters.

The shift from low-single-digit growth in early 2025 to high-single-digit growth in the most recent quarter suggests demand is broadening rather than resting on a single segment. The reported figures do not isolate volume, pricing, or acquisition contributions, so the durability of this acceleration cannot be fully separated from M&A or currency effects. Investors should monitor whether organic growth holds at this level once the comparison base becomes less favorable.

Gross Margin Recovery Driven by Mix

As reported in the quarterly income statements, IEX's gross margin moved from 38.8% in 2024Q4 to 45.1% in 2026Q3, a recovery that appears to reflect pricing realization and a more favorable segment mix.

A roughly six-point gross margin recovery over eight quarters is substantial for an industrial manufacturer and suggests the business retains meaningful pricing power in its niche markets. The margin band between 43% and 46% over most recent quarters points to a more stable structural level than the 2024Q4 trough. Whether this level holds will depend on input cost trends in specialized metals and polymers, which the provided data does not break out.

Operating Leverage Limited by Flat SG&A

Based on the reported figures, IEX's operating margin reached 21.9% in 2026Q3 while SG&A held near $218M, indicating that incremental gross profit is flowing through to operating income at a healthy rate.

Operating income of $208.0M on gross profit of $429.5M implies that a large share of gross profit growth is converting to operating earnings, consistent with disciplined overhead control. SG&A has remained within a narrow range in recent quarters, which suggests cost discipline rather than heavy reinvestment in the sales base. The operating margin trajectory is encouraging, though the provided data does not show a clean separation between structural efficiency and timing effects.

EPS Growth Outpacing Net Income Volatility

According to reported quarterly results, IEX's diluted EPS grew 14.7% year over year in 2026Q3 to $1.95, while net margin of 15.1% reflects a relatively steady earnings conversion from operating income.

EPS growth in recent quarters has been uneven, including a sharp decline in 2024Q3 and a rebound in 2026Q1, which points to sensitivity to below-the-line items or share count changes. Stock-based compensation remains modest relative to revenue, lowering concern about dilution-driven earnings quality. The provided data does not detail tax rate or non-operating items, so those components cannot be fully assessed and warrant further investigation.

Cost of Goods Sold Scaling Below Revenue

As reported in the financial statements, IEX's COGS equaled 54.9% of revenue in 2026Q3, compared with roughly 61% in 2024Q4, suggesting improved input cost absorption as volumes and pricing evolved.

The compression of cost of goods sold as a share of revenue points to better pricing or procurement outcomes rather than a simple volume effect. R&D is not separately reported in the supplied data, so the company's investment intensity in its life sciences exposure cannot be benchmarked. Management's expense discipline appears evident in stable SG&A, though sustained gains will depend on whether specialized material costs remain contained.

Late 2024 Margin Trough as Inflection Point

Based on IEX's reported figures, gross margin fell to 38.8% in 2024Q4 before recovering above 44% by 2025Q3, marking the most significant operational inflection in the ten-quarter history.

The sharp dip in gross margin during late 2024, paired with a 2024Q4 EPS figure that still grew year over year, suggests a transitory cost or mix shock rather than a structural break. The subsequent recovery to the mid-40s range implies the company restored pricing and cost alignment within several quarters. Investors should monitor whether this recovery reflects durable operating improvements or a favorable comparison against an unusually weak base.

Margin Gains May Prove Cyclical

The strongest counter-view holds that IEX's recent gross margin expansion may reflect favorable timing rather than durable structure, with the sequential EPS guidance decline suggesting momentum may be peaking.

Revenue growth of 8.3% paired with a 14.7% EPS increase in 2026Q3 may overstate underlying trends if SG&A leverage or gross margin gains reflect timing effects. Sequential softness implied by forward guidance could signal that the recent margin peak is already behind the company. Investors should monitor whether gross margins can sustain the mid-40s range if biopharma demand softens or input costs rise.

IEX — Frequently Asked Questions

Quick answers to the most common questions about buying IEX stock.

What was IDEX Corporation's (IEX) revenue in 2025?

For fiscal year 2025, IDEX Corporation (IEX) reported total revenue of $3.46B. This represents a 514.6% increase compared to $562.6M in 1996.

Is IDEX Corporation (IEX) profitable?

IDEX Corporation (IEX) is profitable, generating $483.2M in net income for the fiscal year ending 2025 with a net profit margin of 14.0%.

What is IDEX Corporation's operating profit margin?

IDEX Corporation (IEX) reported an operating income of $720.0M, resulting in an operating profit margin of 20.8%. This margin reflects the operational efficiency of the business before interest and taxes.

What is IDEX Corporation's gross profit and gross margin?

IDEX Corporation (IEX) generated $1.54B in gross profit for the year, representing a gross profit margin of 44.5%. This demonstrates the company's core pricing power and production efficiency.